Tuesday, August 01, 2023
Amarin Corporation and Lotus Pharmaceuticals have entered into significant long-term exclusive partnership to distribute and commercialise VAZKEPA® (icosapent ethyl) in ten countries.
As per the agreement between Amarin Corporation and Lotus Pharmaceuticals, Lotus will have exclusive rights to distribute and carry out commercial promotion for VAZKEPA® in South Korea and nine countries within the Association of Southeast Asian Nations (ASEAN). These countries include Brunei, Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam.
Under the terms of agreement, Amarin Corporation will receive an upfront payment, pricing and reimbursement benefits, and sales milestone payments. These payments will be based on the net sales of VAZKEPA® in the regions covered by the agreement.
VAZKEPA® capsules have received approval and have been successfully commercialised in various markets, including the United States and European countries as the first prescription treatment comprised solely of the active ingredient icosapent ethyl, which is a highly purified form of eicosapentaenoic acid (EPA).
This partnership agreement aims to bring innovative and transformative treatments to patients.